23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Teva Pharmaceutical Industries Limited › 2025-2026

Teva Pharmaceutical Industries Limited 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Teva Pharmaceutical Industries Limited’s Form 8-K, filed May 28, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Reported items
  • 620Asset managers, any item
  • 1,860Fund votes
  • May 28, 2026Meeting date

Results at a glance

Meeting of May 28, 2026: 3 items on Teva Pharmaceutical Industries Limited’s Form 8-K, filed May 28, 2026: 2 approved · 1 passed (calculated).

Dissent

Significant dissent: 1 director (28.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Teva Pharmaceutical Industries Limited in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Teva Pharmaceutical Industries Limited

These tallies are Teva Pharmaceutical Industries Limited’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Teva Pharmaceutical Industries Limited — official shareholder meeting results, meeting held May 28, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Sol J. Barer 627,816,662245,921,571530,682 --50,661,570 72%Passed (calculated)—
2. On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting 795,976,04277,082,8471,170,026 --50,661,570 91%Approved—
3. The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2027 annual meeting of shareholders 880,542,24236,085,507525,382 --0 96%Approved—

Source: Teva Pharmaceutical Industries Limited, Form 8-K, filed with the SEC on May 28, 2026 — read the filing on EDGAR.

How asset managers voted at the Teva Pharmaceutical Industries Limited 2025-2026 meeting

620 asset managers disclosed a vote on at least one Teva Pharmaceutical Industries Limited item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Teva Pharmaceutical Industries Limited’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Dr. Sol J. Barer

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST
FOR: 627,816,662AGAINST: 245,921,571
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: To appoint Dr. Sol J. Barer to serve as a director until Teva's 2029 Annual Meeting of Shareholders

Teva Pharmaceutical Industries Limited’s own tally for this item (“Elect Director: Dr. Sol J. Barer”): 627,816,662 for, 245,921,571 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 155,718,632 for, 2,045,492 against, 59,891 abstained, 336,890 not voted.

FOR
FOR: 155,718,632AGAINST: 2,045,492ABSTAIN: 59,891NOT VOTED: 336,890
Largest asset managers voting on “To appoint Dr. Sol J. Barer to serve as a director until Teva's 2029 Annual Meeting of Shareholders” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity31,361,1060 00For
Vanguard31,267,7160 00For
BlackRock27,277,6440 00For
Investment Managers Series Trust13,399,6600 00For
NEW ECONOMY FUND5,843,8120 00For
Capital Group5,011,0350 00For
Charles Schwab4,414,9890 00For
TIAA2,550,5480 00For
Jackson National2,511,68416,909 00For
OLD WESTBURY FUNDS INC2,446,4460 00For
Bridge Builder Trust2,353,5270 00For
Lord Abbett2,232,4240 00For
Hartford2,050,8900 00For
State Street2,047,3600 00For
JANUS INVESTMENT FUND2,036,6470 00For
Invesco1,876,0800 00For
Victory Capital1,767,8380 00For
VanEck ETF Trust1,448,8900 00For
SOUND SHORE FUND INC1,269,5050 00For
First Trust1,160,5210 00For
Prudential/PGIM996,9000 00For
Allspring907,1210 00For
Dimensional0892,174 00Against
DWS615,3370 00For
MARSICO INVESTMENT FUND574,2180 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 24 wordings of this item as funds reported it.

91% Approved · of votes cast

FOR 91%
FOR: 795,976,042AGAINST: 77,082,847

Prior year: 87.4% for (June 5, 2025 meeting) ▲ 3.8 pts

Details: description as filed, official tally, votes by 620 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERS

Teva Pharmaceutical Industries Limited’s own tally for this item (“2. On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting”): 795,976,042 for, 77,082,847 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 104 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERS” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity31,361,1060 00For
Vanguard31,267,7160 00For
BlackRock27,277,6440 00For
Investment Managers Series Trust13,399,6600 00For
NEW ECONOMY FUND5,843,8120 00For
Capital Group5,011,0350 00For
Charles Schwab4,414,9890 00For
TIAA2,550,5480 00For
Jackson National2,528,5930 00For
OLD WESTBURY FUNDS INC2,446,4460 00For
Bridge Builder Trust2,353,5270 00For
Lord Abbett2,232,4240 00For
Hartford2,050,8900 00For
State Street2,047,3600 00For
JANUS INVESTMENT FUND2,036,6470 00For
Invesco1,876,0800 00For
Victory Capital1,767,8380 00For
VanEck ETF Trust1,448,8900 00For
SOUND SHORE FUND INC1,269,5050 00For
First Trust1,160,5210 00For
Prudential/PGIM996,9000 00For
Allspring907,1210 00For
Dimensional892,1740 00For
DWS615,3370 00For
MARSICO INVESTMENT FUND574,2180 00For

Fund voting reports, all 104 managers: 157,511,409 for, 11,884 against, 59,891 abstained, 336,890 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 542 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERS” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Harel Insurance Investments & Financial Services Ltd.77,246,8860 00For
Migdal Insurance & Financial Holdings Ltd.60,694,1200 00For
Phoenix Financial Ltd.54,504,0190 00For
MENORA MIVTACHIM HOLDINGS LTD.53,937,2020 00For
BlackRock42,982,2410 00For
WCM INVESTMENT MANAGEMENT, LLC39,330,5160 00For
Clal Insurance Enterprises Holdings Ltd37,718,0890 00For
Fidelity33,312,3890 00For
State Street15,854,19758,957 00For
Vanguard12,682,7120 00For
Capital Group11,674,1710 00For
Altshuler Shaham Ltd011,463,884 00Against
GEODE CAPITAL MANAGEMENT, LLC10,605,6320 00For
Polar Capital Holdings Plc10,209,3440 00For
Janus Henderson9,449,8450 00For
Y.D. More Investments Ltd08,426,222 00Against
Northern Trust6,591,4260 00For
GLENVIEW CAPITAL MANAGEMENT, LLC6,148,0150 00For
Wellington5,658,3240 00For
Invesco5,431,1470 00For
Legal & General Investment Management Ltd63,8404,990,570 00Against
Charles Schwab4,620,8510 00For
ION Fund Management Ltd3,883,1830 00For
AustralianSuper Pty Ltd03,793,078 00Against
Alyeska Investment Group, L.P.3,773,3430 00For

Institutional-manager reports, all 542 managers: 601,844,436 for, 41,765,418 against, 352,705 abstained, 28,591 not voted, 585,954 1 year. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 880,542,242AGAINST: 36,085,507
Details: description as filed, official tally, votes by 108 asset managers

Description as filed by funds: TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2027 ANNUAL MEETING OF SHAREHOLDERS

Teva Pharmaceutical Industries Limited’s own tally for this item (“3. The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2027 annual meeting of shareholders”): 880,542,242 for, 36,085,507 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2027 annual meeting of shareholders, as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 108 asset managers below reported 156,015,752 for, 809,305 against, 59,891 abstained.

FOR
FOR: 156,015,752AGAINST: 809,305ABSTAIN: 59,891
Largest asset managers voting on “TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity31,361,1060 00For
Vanguard31,267,7160 00For
BlackRock27,277,6440 00For
Investment Managers Series Trust13,399,6600 00For
NEW ECONOMY FUND5,843,8120 00For
Capital Group5,011,0350 00For
Charles Schwab4,414,9890 00For
TIAA2,550,5480 00For
OLD WESTBURY FUNDS INC2,446,4460 00For
Bridge Builder Trust2,353,5270 00For
Jackson National2,333,7400 00For
Lord Abbett2,232,4240 00For
Hartford2,049,6591,231 00For
State Street2,047,3600 00For
JANUS INVESTMENT FUND2,036,6470 00For
Invesco1,876,0800 00For
Victory Capital1,767,8380 00For
VanEck ETF Trust1,448,8900 00For
SOUND SHORE FUND INC1,269,5050 00For
First Trust1,160,5210 00For
Prudential/PGIM996,9000 00For
Allspring907,1210 00For
Dimensional892,1740 00For
DWS615,3370 00For
MARSICO INVESTMENT FUND574,2180 00For

Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).

Ratify Kesselman & Kesselman as Auditors

100% Fund and manager reports combined; may count the same shares twice · no official result

FORNOT VOTED
Details: votes by 3 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 2 asset managers voting on “Ratify Kesselman & Kesselman as Auditors” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
JPMorgan00 00Not Voted
Empower209,1040 00For

Fund voting reports, all 2 managers: 209,104 for, 336,890 not voted.

Institutional-manager reports: 1 asset manager voting on “Ratify Kesselman & Kesselman as Auditors” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Dorsey Wright & Associates240,6740 00For

Institutional-manager reports, all 1 managers: 240,674 for.

Ratify kesselman and kesselman as auditors

No official matchAUDIT-RELATED

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 3 asset managers

Description as filed by funds: RATIFY KESSELMAN AND KESSELMAN AS AUDITORS

The 3 asset managers below reported 489,289 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 489,289
Largest asset managers voting on “RATIFY KESSELMAN AND KESSELMAN AS AUDITORS” at Teva Pharmaceutical Industries Limited, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Tidal Trust IV216,1160 00For
Jackson National194,8530 00For
John Hancock78,3200 00For

Largest Teva Pharmaceutical Industries Limited shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,164,426,972 shares outstanding at the time of that meeting.

Fund voting reports: top Teva Pharmaceutical Industries Limited shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 2.69%
2Vanguard 2.69%
3BlackRock 2.34%
4Investment Managers Series Trust 1.15%
5NEW ECONOMY FUND 0.50%
6Capital Group 0.43%
7Charles Schwab 0.38%
8TIAA 0.22%
9Jackson National 0.22%
10OLD WESTBURY FUNDS INC 0.21%
Institutional-manager reports: top Teva Pharmaceutical Industries Limited shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1Harel Insurance Investments & Financial Services Ltd. 6.63%
2Migdal Insurance & Financial Holdings Ltd. 5.21%
3Phoenix Financial Ltd. 4.68%
4MENORA MIVTACHIM HOLDINGS LTD. 4.63%
5BlackRock 3.69%
6WCM INVESTMENT MANAGEMENT, LLC 3.38%
7Clal Insurance Enterprises Holdings Ltd 3.24%
8Fidelity 2.86%
9State Street 1.37%
10Vanguard 1.09%

Reported Teva Pharmaceutical Industries Limited holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Teva Pharmaceutical Industries Limited holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Harel Insurance Investments & Financial Services Ltd72,325,555 6.21%Schedule 13G, filed February 9, 2026
BlackRock65,136,464 5.59%Form 13F, quarter ended March 31, 2026
Migdal Insurance & Financial Holdings Ltd61,689,363 5.30%Schedule 13G, filed February 17, 2026
FMR (Fidelity)33,132,795 2.85%Form 13F, quarter ended March 31, 2026
State Street17,790,020 1.53%Form 13F, quarter ended March 31, 2026
Geode Capital10,564,988 0.91%Form 13F, quarter ended March 31, 2026
Morgan Stanley8,444,801 0.73%Form 13F, quarter ended March 31, 2026
Northern Trust7,635,688 0.66%Form 13F, quarter ended March 31, 2026
Wellington Management7,251,828 0.62%Form 13F, quarter ended March 31, 2026
JPMorgan Chase6,762,744 0.58%Form 13F, quarter ended March 31, 2026

Percentages above are of 1,164,426,972 shares outstanding, as reported by Teva Pharmaceutical Industries Limited on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Teva Pharmaceutical Industries Limited's shareholder meeting held May 28, 2026, in the 2025-2026 proxy season, 620 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,860 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE… — Teva Pharmaceutical Industries Limited's filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Teva Pharmaceutical Industries Limited's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Teva Pharmaceutical Industries Limited’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Teva Pharmaceutical Industries Limited proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Teva Pharmaceutical Industries (TEVA) 2026 Annual Meeting”, https://proxyvotesnow.com/company/teva-pharmaceutical-industries-ltd/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.